The retinoblastoma tumor suppressor protein (pRB) is a major regulator of cell-cycle progression and cellular differentiation. Central to pRB function is the pocket domain, which serves as the main binding region for cellular regulators. In tumors pRB is frequently inactivated by mutations in the pocket domain or by binding of viral oncoproteins to this region. A characteristic feature of these viral oncoproteins and many cellular pRB-binding partners is an LxCxE sequence motif, which interacts with pRB's pocket domain. Here, we show that the ubiquitinlike modifier SUMO is covalently attached to a distinct residue (K720) of pRB within the B-box of the pocket region that binds LxCxE-motif proteins. We provide evidence that SUMO preferentially targets the active, hypophosphorylated form of pRB and show that tumorigenic mutations of pRB in the pocket domain lead to a loss of SUMOylation. Notably, the level of pRB SUMOylation is controlled by the interaction of pRB with viral and cellular LxCxE-motif proteins. Inhibitors of pRB function, including the viral oncoproteins E1A and E7 and the cellular E1A-like inhibitor of differentiation EID-1, completely abolish SUMO modification of pRB. Conversely, pRB mutants deficient in binding of LxCxE-motif proteins exhibit a drastically enhanced modification by SUMO. Finally, we provide evidence that SUMOylation can influence pRB function, as the SUMO-deficient pRB K720R mutant exerts a slightly higher repressive potential on an E2F-responsive reporter gene than wildtype pRB. Taken together, these data identify SUMO modification as a novel post-translational modification of pRB that may control pRB activity by modulating LxCxE-pocket interactions.
Introduction
The retinoblastoma-susceptibility gene product pRB is a prototypical tumor suppressor (Classon and Harlow, 2002; Sherr, 2004) . pRB plays a critical role in the control of cell proliferation and differentiation. The inhibitory role of pRB on cell-cycle progression is mainly linked to the repression of E2F-dependent transcription of genes that are required for entry into S phase. Binding of pRB masks the transactivation domain of E2F, thereby directly preventing E2F-dependent gene activation. Additionally, pRB recruits chromatin-remodelling factors of the SWI/SNF family and co-repressor complexes, containing histone deacetylases (HDACs) and methyltransferases, to promoters to silence E2F target genes (Harbour and Dean, 2000) . The pRB-mediated repression of E2F is relieved upon sequential phosphorylation of pRB by the cyclindependent kinase complexes cyclinD-CDK4/6 and cyclinE-CDK2.
In addition to its role in cell-cycle control, pRB is crucial for terminal differentiation and controls adipogenic, myogenic and osteogenic differentiation programs. In these processes pRB appears to function independently of E2F-repression, but likely acts as a coactivator of transcription factors that govern cell differentiation (Liu et al., 2004) .
In neoplastic cells, the pRB pathway is inactivated by mutation/deletion of pRB or by alterations in upstream components of the pathway, such as loss of the CDK inhibitor p16 or overexpression of cyclinD1 or CDK4 (Sherr and McCormick, 2002) . Importantly, pRB is also a direct target of viral oncoproteins, such as the papillomavirus E7 protein, the adenovirus E1A protein and the SV40 largeT antigen. Viral oncoproteins and most cellular interactors of pRB bind to a highly conserved region termed pocket domain. This domain is central for pRB function and defines the 'pocket protein' family, which includes the pRB-related members p107 and p130. Most of the pRB alterations in tumors affect the pocket domain. The pocket can be structurally subdivided in an A-and a B-box. While E2F binds at the interface of the A-and B-Box (Lee et al., 2002; Xiao et al., 2003) , viral proteins and most corepressors bind to pocket B (Brehm et al., 1998; Magnaghi-Jaulin et al., 1998; Nielsen et al., 2001) . A characteristic feature of viral and many cellular proteins that target pocket B is the presence of a short LxCxE sequence motif, which binds to a hydrophobic groove in the B domain (Lee et al., 1998; Kim et al., 2001) .
Post-translational modification of lysine residues with ubiquitin and ubiquitin-like proteins controls the activity of many cellular key factors. The ubiquitin-like SUMO modifier is conjugated to proteins that are involved in central processes, such as nuclear transport, transcription, signal transduction, genome stability and cell-cycle progression (Melchior, 2000; Muller et al., 2001; Seeler and Dejean, 2003) . The currently available data suggest that SUMO regulates protein-protein interactions and in some particular cases is implicated in the regulation of subcellular localization. In humans at least three SUMO forms are expressed from distinct genes. Conjugation of SUMO generally involves the ATP-dependent dimeric SUMO activating E1 enzyme (AOS1/UBA2) and the E2 conjugating enzyme Ubc9. At least in some cases, E3-like factors stimulate conjugation and act as specificity factors in the modification pathway (Johnson and Gupta, 2001; Pichler et al., 2002; Kagey et al., 2003; Schmidt and Muller, 2003) .
Transcription factors and transcriptional co-regulators represent a particular large subgroup of cellular SUMO target proteins indicating that SUMO is critical in the control of transcriptional processes (Verger et al., 2003; Muller et al., 2004) . This led us to investigate whether pRB, which predominantly acts as a regulator of transcription, may undergo modification by SUMO. We identified SUMOylation as a novel post-translational modification of pRB, which targets a specific residue in the lysine cluster of pocket B region and demonstrate that SUMOylation is controlled by binding of LxCxE-containing proteins to the pocket region.
Results

pRB is covalently modified by SUMO
To investigate whether pRB is targeted by SUMO, an HA-tagged version of pRB was expressed together with either untagged or His-tagged SUMO-1 in the pRBnegative C33a cell-line. Western blotting performed with an anti-HA antibody on whole-cell extracts detected the characteristic doublet band corresponding to the hypoand hyperphosphorylated pRB species migrating at about 110 kDa (Figure 1a) . Coexpression of SUMO led to the formation of a slower migrating anti-HAreactive pRB species with an apparent molecular weight of about 130 kDa. In extracts from His-SUMO transfected cells, the His-SUMO-pRB form is slightly upshifted and could be specifically recovered on Ni-NTA beads, indicating that it corresponds to a covalent SUMO-pRB conjugate. Importantly, a SUMO modified form of endogenous pRB was also specifically enriched on Ni-NTA beads upon expression of His-SUMO in U2OS cells, which express wild-type pRB (Figure 1b) . To further validate these findings, we studied SUMO modification of pRB in a reconstituted in vitro system, where in vitro translated 35 S-labelled pRB is incubated with the recombinant SUMOylation machinery, consisting of E1, Ubc9 and SUMO-1. Consistent with the in vivo data, addition of the assay components efficiently triggered the formation of a pRB-SUMO conjugate Figure 1c) . Modification of pRB with SUMO-1 was also obtained in a fully recombinant system, where a bacterially expressed GST-pRB fusion protein spanning the 'large pocket' region (amino acids 379-928) served as a substrate (Figure 1d ). Replacing SUMO-1 by SUMO-2 in the assay mix led to the formation of a pRB-SUMO-2 conjugate indicating that both SUMO-1 and SUMO-2 can target pRB.
A characteristic feature of SUMO target proteins is their ability to interact with the SUMO specific E2-enzyme Ubc9. To investigate the physical interaction of pRB with Ubc9, we performed an in vitro GSTpulldown assay, where in vitro translated 35 S-labelled pRB was incubated with bacterially expressed GSTUbc9. As shown, pRB was specifically retained on beads charged with GST-Ubc9, but did not bind to GST alone (Supplementary Figure 1) .
SUMOylation preferentially targets the hypophosphorylated form of pRB and requires the integrity of the pocket domain
To determine the phosphorylation state of the SUMOpRB conjugate, we first performed immunoblots with an antibody specifically directed against the hypophosphorylated form of pRB ( Figure 2a ). As expected, this antibody exclusively recognizes the faster migrating hypophosphorylated species of the unmodified pRB form and, additionally, detects the SUMO-pRB conjugate indicating that SUMO is conjugated to a hypophosphorylated pRB species. To further substantiate this view, we studied SUMOylation of a pRB mutant (HA-pRB DCDK ) (Lukas et al., 1997) , which lacks 10 CDK consensus phosphorylation sites and as a consequence is constitutively hypophosphorylated. Accordingly, in contrast to wild-type pRB, pRB DCDK migrates as a single band on SDS-PAGE (Figure 2b ). Coexpression of SUMO led to an efficient modification of HApRB DCDK supporting our interpretation that SUMO targets hypophosphorylated pRB ( Figure 2b ). Next, we investigated the interplay between phosphorylation and SUMOylation by expressing regulators of pRB phosphorylation (Figure 2c) . Expression of the CDK2 inhibitor p21 converts the unmodified form of pRB in the faster migrating hypophosphorylated species. Concomitantly, the amount of the SUMO-pRB conjugate is slightly increased, while its electrophoretic mobility remained unaltered indicating that SUMO-pRB represents a form of pRB that lacks phosphorylation at sites targeted by CDK2. Consistent with this interpretation, expression of a dominant-negative CDK2, which triggered the formation of hypophosphorylated pRB, did not change the mobility of the SUMO-pRB conjugate. By contrast, overexpression of cyclin E, which activates CDK2 and quantitatively shifts pRB to the slower migrating hyperphosphorylated species is accompanied by an almost complete disappearance of the SUMO-pRB form indicating that phosphorylation of pRB at cyclinE/CDK2 sites negatively regulates the SUMOylation.
The tumor suppressor function of pRB depends on the integrity of the pocket domain (Classon and Harlow, 2002) . To investigate whether this region is implicated in the SUMOylation process, we studied the modification of two tumorigenic pRB mutant proteins, pRB C706Y and pRB
C712R
. These mutants harbor single amino-acid substitutions in pocket B that originate from germline mutations. Structural studies suggest that these amino-acid exchanges likely disrupt the structural integrity of the pocket domain (Lee et al., 2002) . Strikingly, in contrast to wild-type pRB, neither pRB C706Y nor pRB C712R were modified by SUMO in vivo ( Figure 2d ) and both mutants failed to undergo modification in an in vitro modification assay ( Supplementary Figure 2) , strongly indicating that SUMOylation requires the structural integrity of the pocket domain.
Lysine residue 720 serves as the SUMO attachment site Based on the above findings we reasoned that the SUMO attachment site of pRB might reside in the pocket region. To identify the attachment site, a number of lysine residues within this region were changed to arginine, either individually or in combination, and the resulting pRB mutants were tested for their ability to undergo modification. Mutation of three lysine residues (K462, 537 and 745) that reside in a context that matches the cKxE 'consensus' sequence, which is typically targeted by SUMO, did not alter SUMOylation (Supplementary Figure 3) . By contrast, expression of His-SUMO-1 with a double mutant pRB K720,722R or a single mutant pRB
K720R
did not lead to the formation of a higher molecular weight band indicative for a SUMOylated species (Figure 3a , upper panel). Moreover, no SUMOylated pRB species could be recovered on Ni-beads demonstrating that pRB K720,722R and pRB K720R are deficient for SUMOylation in vivo (Figure 3a , lower panel). Consistent with the in vivo data, no modification of pRB K720,722R and pRB K720R was observed in an in vitro modification experiment demonstrating that K720 serves as an atypical nonconsensus SUMO attachment site of pRB both in vivo and in vitro (Figure 3b ).
Lysine 720 is part of the so-called lysine cluster in pocket B (Figure 3c ). This region comprises six conserved lysine residues (713, 720, 722, 729, 740, 765 ) that surround the LxCxE binding groove of pocket B (Lee et al., 1998) . Lysine 720 is conserved in mammalian pRB species and is also found in the pRB orthologue from Drosophila RBF. Accordingly, RBF could undergo modification with SUMO in vitro (data not shown). By contrast, K720 is absent in p107, another member of the pocket protein family. Consistent with this finding, p107 could not serve as a substrate for either SUMO-1 or SUMO-2 in vitro (Figure 3d ) or in vivo (data not shown) demonstrating the high specificity of the modification system.
Binding of LxCxE proteins negatively regulates SUMOylation
The lysine cluster region is known to contribute to the interaction of LxCxE proteins with pocket B. Structural (Lee et al., 1998 , used with permission from Nature Publishing group). The LxCxE peptide derived from E7 (yellow) binds to a groove in pocket B. The lysine cluster surrounding the LxCxE binding cleft is shown. The SUMO attachment residue K720 is encircled. Alignment of the pocket B region of mammalian pRB species and Drosophila RBF to the human pocket protein family members p130 and p107. (d) p107 is not targeted by SUMO. pRB and p107 were in vitro translated and incubated either in the absence (À) or presence ( þ ) of the assay mix containing recombinant E1 (AOS1/UBA2), Ubc9 and either SUMO-1 or SUMO-2 SUMO modification of pRB A Ledl et al studies revealed that K713 makes direct contact with the LxCxE peptide (Lee et al., 1998) . The positive charges of the other lysines have been proposed to interact with a stretch of negatively charged residues adjacent to the LxCxE motif of viral and cellular LxCxE proteins (Chan et al., 2001b; Brown and Gallie, 2002; Dick and Dyson, 2002) . These ionic interactions contribute to the stability of LxCxE-pocket interaction. In light of these data, we wished to see whether the adenovirus E1A protein, a prototypical LxCxE-motif protein, would affect SUMOylation of pRB. To address this point we performed an in vitro modification experiment, where bacterially expressed recombinant GST-E1A was added to the reaction mix containing the components of the SUMO conjugation system. Indeed, in the presence of E1A, SUMO modification of pRB was completely lost (Figure 4a ). To further determine whether this depends on the direct physical interaction between E1A and pRB, we performed analogous experiments using mutant versions of either E1A or pRB that have lost the ability to interact with each other due to mutations of critical amino-acid residues in the LxCxE motif and the binding cleft, respectively. The pRB YN756,757FA version, which was previously shown to be deficient in binding to viral oncoproteins (Dick et al., 2000) , was still competent for SUMOylation in the presence of E1A (Figure 4a, left panel) . In accordance with this result, upon conversion of the LxCxE motif into RxRxE, E1A was devoid of the ability to interfere with the modification of pRB (Figure 4a, right panel) .
To extend these findings we wished to see whether cellular LxCxE binding proteins could similarly interfere with SUMO modification of pRB. To this aim we chose EID-1 and HDAC-1 as representative cellular pRB binding proteins that rely on LxCxE-or LxCxE-like interaction motifs. EID-1 is believed to act as an E1A-like inhibitor of cellular differentiation (MacLellan et al., 2000; Miyake et al., 2000; Wen and Ao, 2001 ), while HDAC-1 acts as a transcriptional co-repressor (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) . When added to an in vitro modification assay, HDAC-1 reduced SUMOylation of pRB, but failed to completely block it. At equimolar amounts EID-1 exerted a much stronger repressive effect than HDAC-1 and, like E1A, almost completely inhibited SUMO modification (Figures 4b, upper panel and c) . Both HDAC-1 and EID-1 did not interfere with modification of pRB YN756,757FA (Figure 4c , lower panel). E2F-1, which lacks an LxCxE-motif and was used as a negative control, did not affect SUMOylation of either pRB WT or pRB YN756,757FA . To further investigate whether the LxCxE sequence motif alone is sufficient to compete with SUMOylation of pRB, we added a synthetic peptide corresponding to the LxCxE-containing sequence (DLYCYEQLN) of the papillomavirus E7 protein to an in vitro modification assay. Similarly, to what observed with viral and cellular LxCxE-motif proteins, the peptide strongly inhibited SUMO modification, while a control peptide did not affect the modification (Figure 4c ). In summary, these data demonstrate that binding of LxCxE containing proteins represses SUMOylation of pRB in vitro.
To address the in vivo relevance of these findings, we investigated whether LxCxE containing proteins did alter the SUMOylation of pRB in vivo. To this aim, either the 12S or the 13S splice variant of E1A was coexpressed with pRB and SUMO. The SUMO-pRB conjugate was completely absent after expression of either E1A form (Figure 5a) . Similarly, coexpression of the E7 protein of human papillomavirus and EID-1 almost completely abrogate the SUMOylation of pRB (Figure 5b ), whereas HDAC-1 only reduces the modification. In accordance with the in vitro results, the modification of the pRB YN756,757FA mutant was insensitive to expression of E1A (Figure 5c ). When compared to wild-type pRB, we consistently observed a more efficient modification of pRB YN756,757FA (Figure 5d and e). In particular, both the hypo-and hyperphosphorylated species of pRB YN756,757FA were targeted by SUMO. Importantly, pRB YN756,757FA was readily SUMOylated by endogenous SUMO (Figure 5d, lane 3) , indicating that the accessibility of K720 promotes modification (Figure 5d , lanes 5 and 6). To further confirm that the enhanced modification of pRB YN756,757FA is directly linked to its inability to interact with LxCxE-binding proteins and not to a particular structural feature of this mutant, we included pRB Y709A , another LxCxE-binding deficient mutant in our studies (Dahiya et al., 2000) . Compared to wild-type pRB the modification of pRB Y709A was similarly enhanced (Figure 5e ), suggesting that like pRB YN756,757FA pRB Y709A is protected from the inhibitory function of LxCxE proteins on SUMOylation. Since C33a cells do not express viral oncoproteins, these results demonstrate that both viral and cellular LxCxEcontaining proteins negatively regulate SUMOylation. Moreover, our findings suggest that binding of LxCxE proteins to the pocket B region of pRB and SUMO conjugation are counteracting activities. The inhibitory potential varied between distinct LxCxE proteins likely reflecting their different binding affinities to pRB. We assume that binding of LxCxE containing proteins may mask the SUMO attachment site or prevent access of the SUMOylation machinery.
In light of the above findings, we wished to determine whether modification by SUMO could in turn alter the interaction of LxCxE-containing proteins with pRB's pocket. To address this point, we performed GSTpulldown experiments using E1A and EID-1 as a bait. Glutathione sepharose beads charged with recombinant GST, GST-E1A or GST-EID-1 were incubated with extracts from cells transfected with pRB and SUMO. As shown, the ratio between unmodified pRB and SUMO-pRB retained on GST-E1A or GST-EID-1 was comparable to the ratio of both forms in the extracts indicating that SUMOylation and LxCxE binding are not mutually exclusive (Figure 5f ). Moreover, the data indicate that, at least for these the high-affinity interaction partners of pRB, there is no obvious preference of binding towards modified versus nonmodified pRB.
SUMOylation modulates pRB activity
To investigate whether SUMOylation has an impact on pRB activity we established stable C33a cell-lines, which express either wild-type pRB or pRB K720R from a tetracycline-inducible promoter. The cell-lines were generated using the recombination based Flp-in system, which allows integration of pRB or pRB K720R as a single copy at the same genomic locus and thus ensures equal and moderate expression of both forms in an isogenic background. Since E2F transcription factors are the major targets of pRB function we investigated a potential impact of SUMO on the pRB-mediated undergoes SUMOylation with endogenous SUMO. pRB YN756,757FA was expressed with or without SUMO and extracts were separated by SDS-PAGE and probed with anti-HA antibody. (e) SUMOylation of LxCxE binding deficient pRB mutants is enhanced. C33a cells were cotransfected with plasmids expressing HA-pRB species as indicated, extracts were separated by SDS-PAGE and probed with anti-HA antibody. (f) SUMOylation and binding of LxCxE proteins are not mutually exclusive. GST, GST-E1A or a GST-EID-1 fusion protein were immobilized on glutathione-sepharose beads and incubated with cell extracts from cells transfected with HA-pRB and SUMO. After intensive washing, bound proteins were resolved by SDS-PAGE and detected by immunoblotting with an anti-HA antibody. A Coomassie Blue stained SDS-PAGE gel of the purified GST-fusion proteins is shown at the bottom repression of E2F activity. To this aim SUMO was coexpressed with an E2F-driven luciferase reporter gene in either pRB or pRB K720R cell-lines and reporter gene activity was measured 24 h after the addition of tetracycline. Western blotting confirmed that expression of SUMO triggered modification of wild-type pRB, but not pRB K720R (Figure 6a) . In a series of four experiments carried out in duplicate we consistently observed that pRB K720R downregulated E2F reporter gene activity to a higher extent than the wild-type pRB form (Figure 6b ). The expression of wild-type pRB reduced reporter gene activity on average to 61% when compared to the uninduced control, while expression of pRB K720R led to a mean reduction to 43% of basal activity. Considering that our experimental system guarantees equal expression levels, this moderate, albeit significant difference indicates that SUMO can indeed modulate pRB function. In particular, the data show that the loss of SUMOylation correlates with an increase in pRB's repressive capacity towards E2F.
Discussion
The modification of pRB with the ubiquitin-like SUMO protein described here points to a new aspect in the control of pRB function. Considering that SUMO preferentially targets the hypophosphorylated form of pRB and is repressed by binding of viral and cellular inhibitors, SUMO may modulate pRB's activity in cell proliferation or differentiation. pRB has been reported to physically interact with more than 100 cellular proteins (Morris and Dyson, 2001 ) and distinct posttranslational modifications of pRB, such as acetylation and phosphorylation control the interaction with specific cellular binding partners (Knudsen and Wang, 1996; Zarkowska and Mittnacht, 1997; Chan et al., 2001a; Nguyen et al., 2004; Takaki et al., 2004) . Our finding that SUMO targets pRB within the lysine cluster, which surrounds the LxCxE binding cleft, raises the possibility that SUMO modulates the interaction of pocket B with distinct LxCxE containing proteins. Although binding experiments with EID-1 and E1A show that SUMOylation does not impair interaction with these high-affinity binding partners of pRB, it remains to be determined whether it may alter the interaction properties of pRB to low-affinity binding partners. Alternatively, SUMO might modulate the formation or stability of multimeric complexes on pRB's pocket. Interestingly, the lysine cluster has been proposed to be important for the release of corepressors from the pocket. According to a current model, the positive charges of the lysine cluster are thought to serve as docking sites for the phosphorylated C-terminus (Harbour et al., 1999) . This intramolecular interaction displaces LxCxE proteins, including HDAC, from the pocket, and thus relieves repression of E2F activity by pRB. In the context of this model it is interesting to note that SUMO modification has recently been reported to recruit HDACs to transcriptional regulators (Girdwood et al., 2003; Yang and Sharrocks, 2004) and that HDACs also undergo SUMOylation (David et al., 2002; Kirsh et al., 2002) . Our finding that the SUMO deficient pRB K720R mutant exerts a moderately stronger repressive activity on an E2F-responsive reporter gene points to an inhibitory role of SUMO on the repressive action of pRB and would be consistent with a role of SUMO in the displacement of a transcriptional corepressor or altered binding to E2F family members. However, we currently do not have direct biochemical evidence that SUMOylation of pRB modulates its interaction with HDAC-1 or E2F-1.
Another mechanism of SUMO action appears to be protein targeting, since several examples of a SUMOdependent change in subcellular localization of proteins have been reported. However, subcellular fractionation and immunofluorescence experiments did not reveal a SUMO-dependent change in pRB localization (Ledl et al., unpublished data) .
As for most other substrates of SUMO only a small fraction of pRB is SUMOylated at a given time. One possibility is that SUMO acts on a subpopulation of pRB to modulate specific functions under distinct cellular conditions. As an alternative model, it has been proposed that SUMO exerts is function by a cyclic process of modification and demodification rather than acting stoichiometrically (Johnson, 2004) . In this model, WT or pRB K720R were transfected with an E2F driven luciferase reporter gene together with SUMO. To normalize transfection efficiency, a renilla luciferase reporter was cotransfected. At 24 h after transfection expression was induced by addition of tetracycline and another 24 h later luciferase activity was measured by the dual luciferase system. The reporter activity of uninduced cells was set at 100. Values represent the average of four independent experiments carried out in duplicate with standard deviation after normalization for the internal control renilla luciferase activity. Statistical significance was determined by Student's t-test and levels of probability were Po0.05
SUMO modification of pRB
A Ledl et al the transient attachment of SUMO would be sufficient to promote specific protein interactions, induce a conformational change or trigger subsequent modification to irreversibly alter the function of the substrate despite subsequent demodification. Although SUMO appears to slightly inhibit pRBmediated repression it might positively influence other pRB functions. Our finding that EID-1, which acts as a repressor of differentiation, functions as a strong cellular inhibitor of pRB SUMOylation would be consistent with a role of SUMO in differentiationspecific functions of pRB. In these processes, pRB acts as a coactivator of transcription factors. pRB cooperates with members of the C/EBP family in adipogenesis, stimulates CBFA1/RUNX2 activity in osteogenesis and enhances MyoD activity in myogenesis (Chen et al., 1996a, b; Novitch et al., 1999; Thomas et al., 2001) . It remains to be determined whether SUMOylation has a modulatory effect in any of these processes. However, the finding that EID-1, which acts as a repressor of differentiation, functions as a strong cellular inhibitor of pRB SUMOylation would be consistent with a role of SUMO in differentiation-specific functions of pRB. An involvement of SUMO in differentiation-specific functions would also explain the absence of this modification in p107, since pRB appears to have a unique role in differentiation among the pocket family members.
In summary, we identify SUMOylation as a novel post-translational modification of pRB that targets the LxCxE binding region in pocket B. Considering that most pRB binding proteins require the pocket region for interaction and that a subset of these uses an LxCxE motif for binding, further functional studies, including the generation of a mouse knock-in model with the SUMO-deficient K720R version of pRB, may unravel a crucial role of this modification in pRB function.
Materials and methods
Plasmids, mutagenesis and antibodies
Mammalian and bacterial expression vectors for SUMO-1, His-SUMO-1, p53 and the components of the in vitro SUMOylation assay have been described (Muller et al., 2000) . Plasmids for HA-pRB, E2F-1, p21, CDK2-DN, GSTpRB and HA-pRB DCDK were kindly provided by W Kaelin, K Helin, E Nigg and J Bartek. cDNAs for HDAC-1, EID-1 and cyclinE were isolated by RT-PCR from HeLa cells and cloned into pGex-4T1 (Pharmacia) or pcDNA3 (Invitrogen). Plasmids expressing E1A and E7 were provided by G Akusjarvi and M Scheffner. Site-directed mutagenesis was carried out using the quick-change site directed mutagenesis kit (Stratagene). The monoclonal anti-HA antibody (16B12) was purchased from Covance/BabCo and the monoclonal anti-E1A antibody from PharMingen. pRB was detected with the monoclonal antibody 4H1 (Cell Signalling) or G99-495 (Pharmingen), which is specific for hypophosphorylated pRB.
Development of stable cell lines
To establish the C33a cell-lines expressing tetracyclineinducible HA-pRB and HA-pRB K720R , the tagged cDNAs were cloned into the pcDNA5/FRT vector (Invitrogen), which contains an Flp recombination target (FRT) site. These plasmids were cotransfected with the Flp recombinase expression plasmid pOG44 (Invitrogen), into an Flp-In T-REx C33 host cell line, which had been generated by stably integrating a single FRT site and the tet-repressor using the Flp-In T-Rex core kit according to the manufacturer's instructions. Cells maintaining an integrated copy of the transfected pcDNA5/ FRT vector were selected in medium containing 7.5 mg/ml blasticidin and 200 mg/ml of hygromycin. Upon selection, individual clones were isolated and tested for loss of bgalactosidase activity and zeocin sensitivity, which occurs upon proper insertion at the FRT-site. b-galactosidase negative clones were tested for expression of HA-pRB and HA-pRB K720R upon addition of tetracycline to the culture medium at a concentration of 1 mg/ml.
Cell culture, transfection and Western blotting
C33a and U2OS cells were grown under standard conditions and transfected using the calcium phosphate method or Lipofectamine Plus (Invitrogen). For 3.5 cm diameter cell culture dishes, the total amount of transfected DNA was 4 mg for calcium phosphate or 1.5 mg for Lipofectamine Plus. At 48 h after transfection cells were either directly lysed in SDSsample buffer or used for Ni-NTA precipitation as described previously (Muller et al., 2000) . Western Blotting was carried out using the Western-Star Immunodetection system (Tropix).
Expression of recombinant proteins and in vitro SUMOylation
GST fusion and His-tagged proteins were expressed in Escherichia coli BL21 and the proteins purified on glutathione-sepharose 4B beads (Pharmacia) or Ni-NTA-beads (Quiagen) according to the manufacturer's protocols. In vitro SUMOylation assays were carried out as described (Schmidt and Muller, 2002) . In experiments where the inhibitory role of proteins was studied, 10 pmol of the respective fusion protein or 300 pmol of the LxCxE peptide were used per assay. In vitro translations were carried out by using the TNT quick-coupled reticulocyte lysate system (Promega).
GST-pulldown assays
35 S-methionine-labelled in vitro translated proteins (in 120 mM NaCl, 50 mM Tris pH 8, 0.25% NP-40, 1 mM PMSF, 1 mM DTT) or cell-extracts (in 150 mM NaCl, 50 mM HEPES, 2 mM EDTA, 0.1% NP-40, 20 mM N-ethylmaleimide, protease inhibitors) were incubated for 4 h at 41C with the relevant GST-fusion proteins loaded on glutathione-sepharose 4B beads. Beads were washed three times with binding buffer, bound proteins were eluted with SDS sample buffer and analysed by gel electrophoresis followed by autoradiography or Western Blotting.
Reporter gene assays
Cells were transfected in six-well dishes as described above using 500 ng of SUMO-1 with 500 ng of a firefly luciferase reporter gene plasmid (provided by K Helin) that harbors an E2F DNA-binding site in its promoter. To normalize for transfection efficiency 50 ng of a pRL-SV40 renilla luciferase control vector (Promega) were cotransfected. After 24 h expression of pRB and pRB K720R was induced by addition of tetracycline and after another 24 h cells were lysed in 300 ml of passive lysis buffer and 20 ml of cell extract were analysed with the Dual Luciferase Reporter Assay (Promega) using a Berthold Lumat LB9507 apparatus.
